	US 11,896,628 B2
	Methods and compositions for the treatment of C. difficile
Ronald Farquhar, Boston, MA (US); Christopher K. Murphy, Dublin (IE); Colin Hill, Dublin (IE); Paul Ross, Dublin (IE); Mary Rea, Fermoy (IE); Michelle O'Donnell, Waterford (IE); Brian Healy, Mallow (IE); and Laurent Chesnel, Bedford, MA (US)
Assigned to Artugen Therapeutics Ltd., Dublin (IE)
Filed by Artugen Therapeutics Ltd., Dublin (IE)
Filed on Jul. 1, 2022, as Appl. No. 17/856,013.
Application 17/856,013 is a continuation of application No. 15/734,747, granted, now 11,419,900, previously published as PCT/US2019/035740, filed on Jun. 6, 2019.
Claims priority of provisional application 62/681,774, filed on Jun. 7, 2018.
Prior Publication US 2023/0132133 A1, Apr. 27, 2023
Int. Cl. A61K 35/74 (2015.01); A61P 1/12 (2006.01); A61K 9/19 (2006.01); A61K 45/06 (2006.01); A61K 47/36 (2006.01)

CPC A61K 35/74 (2013.01) [A61K 9/19 (2013.01); A61K 45/06 (2013.01); A61K 47/36 (2013.01); A61P 1/12 (2018.01)]

15 Claims

1. A method of preparing a therapeutic composition, comprising, combining one or more bacterial strains selected from the group consisting of ART24 (NCIMB Accession No. 43088), ART4 (NCIMB Accession No. 43086), and ART12 (NCIMB Accession No. 43087) With a preservative.